The global molecular cytogenetics market size was estimated at USD 1.5 billion in 2016. Cytogenetic analysis was earlier limited to the investigation of cellular aspects that covered the detection of genomic aberrations and the study of chromosomal structure in heredity conditions. In the current scenario, the cytogenetic analysis goes beyond the simple investigation of the chromosomal status of the genome. This has accelerated the study of chromosomal changes that are involved in disease pathogenesis, three-dimensional organization of the human genome, and the nature of inherited syndromes.
Currently, the most important goal of human genetics is to bridge the gap between clinical applications of genetic findings and accordingly provide a refined medical service. Growth in utilization of genetic information in predictive models for disease traits has a direct impact on the adoption of cytogenetic tools, thereby boosting revenue generation.
Increasing the incidence of cancer and related growth in mortality per year has significantly driven the market. The continued rise in new cancer cases has emphasized the need for the development of advanced technologies for a comprehensive understanding of cancer at a genomic level.
FISH and Comparative Genomic Hybridization (CGH) are among the most recognized cytogenetic techniques as they provide thorough information about cancer-related molecular signatures. These methods aid in gaining insights into cancer progression.
Growing activities in pharmacogenomics are anticipated to significantly impact market growth as several cytogenetic tools have been successfully used for pharmacogenomic biomarker studies. Effective use of CGH, FISH, and sequencing technology in pharmacogenomics is evident by the presence of a substantial number of published articles demonstrating the role of cytogenetic techniques in pharmacogenomic testing.
Ongoing technological advancements in CGH and FISH, with respect to resolution and specificity, have augmented the application scope of cytogenetics tools in basic research and molecular diagnostics. These advancements have successfully overcome the limitations of conventional cytogenetic analysis.
Lack of predictable coverage and reimbursement policies for new genomic tools could hinder the application of molecular cytogenetics in cancer and personalized care. Moreover, the dearth of skilled personnel and high expense associated with the maintenance and handling of advanced techniques are expected to impede the market in the future.
A thorough understanding of genomes is fundamental to achieving several objectives of cancer management: therapeutic strategies, fast and precise diagnosis, survival prediction, and recurrence risk estimation. Effective and high usage of molecular cytogenetic techniques for in-depth cancer studies has enabled oncology to emerge as the largest application segment.
Pharmacotherapies and personalized treatment options are recognized as the two most important strategies for achieving improved treatment outcomes. With a shift toward personalized medicine, the use of molecular cytogenetic techniques is expected to grow lucratively throughout the forecast period. This is mainly because molecular cytogenetic analysis has proven to be vital in personalized medicine through its wide applications in cytoproteomics, cytogenomics, drug discovery and development, and biomarker discovery.
The molecular cytogenetics market offers a broad range of products, such as instruments/equipment, consumables, and software and services. Advances in molecular biology techniques have also propelled the development of associated consumables, reagents, kits, and software.
Rising usage of media and reagents while performing cytogenetic analysis has rendered consumables as the largest segment. Consumables assist in gaining accurate and reproducible results in standard as well as advanced clinical cytogenetic protocols.
However, in the coming years, software and services are expected to serve as a lucrative source of revenue owing to ongoing development in solutions and algorithms to manage and interpret massive amounts of genomic data.
Ongoing genomic research activities have resulted in surplus volumes of genomic findings. This, in turn, has propelled companies to invest in the development of robust and sophisticated software and algorithms to simplify cytogenetic analysis.
Clinical and research laboratories dominated the market in 2016. This is majorly due to the growing implementation of cytogenetic techniques in clinical diagnosis. Ongoing research pertaining to pathways underlying various chromosomal diseases has enabled this segment to attain the largest share.
With the growing demand for targeted therapies, the implementation of molecular cytogenetics in pharmaceutical and biotech companies is expected to grow at a lucrative pace. The popular trend of companion diagnostics is also expected to support the growth of this segment throughout the forecast period.
Availability, turnaround time, cost, and specificity are key factors that play a significant role in the adoption of cytogenetic techniques. In the current scenario, CGH and FISH techniques are widely adopted across various applications such as diagnostics, research activities, and medicine development.
The many advantages of CGH and FISH techniques offer over conventional techniques that have allowed these segments to account for a major share in the market. CGH captured the dominant share owing to its vital role in comprehensive cancer studies. The high resolution offered by array-based CGH has also contributed to its growth. Array-based CGH has significantly addressed the limitations of standard CGH with respect to labor requirements and resolution. This technique has also eliminated the need for metaphase chromosomes, which results in enhanced resolution.
North America accounted for the largest share in 2016 mainly due to the local presence of major entities, such as Agilent Technologies, Inc. Moreover, the presence of an effective regulatory framework for the regulation of genetic tests has significantly propelled the regional market.
Asia Pacific is expected to emerge as the fastest-growing regional market during the course of the forecast period. Continuous GDP growth of countries such as China and India is anticipated to enhance consumer buying power and drive regional growth. Ongoing workshops and interventions in Asia Pacific pertaining to current trends and developments in human genetics and disease management are driving the Asian market. These workshops are aimed at improving awareness about the significance of advanced diagnostics and therapies among the population.
BIOVIEW; Danaher; MetaSystems; Agilent Technologies, Inc.; Abbott; Bio-Rad Laboratories, Inc.; Illumina, Inc.; Oxford Gene Technology; F. Hoffmann-La Roche Ltd.; PerkinElmer Inc.; Quest Diagnostics Incorporated; Applied Spectral Imaging; Biological Industries USA, Inc.; CytoTest; Cytognomix; Genial Genetics; and Diagnostic Cytogenetics, Inc. (DCI) are some of the prominent players operating in the market. These players are engaged in the manufacturing and marketing of cytogenetic tests and techniques for service providers.
Understanding the growing demand for cytogenetic analysis amongst the population, manufacturers are making significant investments to broaden their product portfolio. They are also engaging in mutually beneficial partnerships with laboratories and research institutes, which in turn, boost revenue generation for these companies.
Some service providers that offer cytogenetic technique-based services are Weill Cornell Medicine; UCLA Health - UCLA Pathology and Laboratory Medicines; OHSU School of Medicine-Molecular and Medical Genetics; Integrated Systems Engineering S.r.l.; WiCell Research Institute, Inc.; Virtual Scientific; UW Cytogenetic Services; Genesis Laboratories Inc.; Calgary Laboratory Services; Neogenomics; ARUP Laboratories; and South West Thames Regional Genetics Service.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global molecular cytogenetics market report on the basis of application, product, end use, technology, and region:
Application Outlook (Revenue, USD Million, 2014 - 2025)
Product Outlook (Revenue, USD Million, 2014 - 2025)
Software & Services
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Clinical & Research Laboratories
Hospitals & Pathology Laboratories
Academic Research Institutes
Pharmaceutical and Biotechnology Companies
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Comparative Genomic Hybridization
Array-based comparative genomic hybridization
Standard comparative genomic hybridization
Fluorescence In Situ Hybridization (FISH)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.